V
vTv Therapeutics Inc. (VTVT)
38.51
0.00 (0.00%)
Get all premium features to the best stock analysis tool
38.51
0.00 (0.00%)
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 13.54 | 6.05 | 10 | |
| Quick ratio | 13.54 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | -7885.00 | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 2M | N/A | 1M | N/A | N/A |
| Gross Profit | 2M | -90K | 928K | -16K | -16K |
| Operating Income | -23M | -26M | -24M | -33M | -33M |
| Net Income | -19M | -20M | -18M | -27M | -27M |
| EBITDA | -22M | -25M | -24M | -33M | -33M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 59.31 | 5.5 |
| Next quarter | N/A | -1.09 | 1.0 |
| Current year | N/A | 11.35 | 4.0 |
| Next year | -92 | -31.32 | 1.0 |
| Weighted average score | 2.9 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 17.94 | 46.3 | -91.52 | 7.5 |
| Y/Y | -99.99 | -96.41 | -5.44 | -91.72 | 1.0 |
| 3y average | 266.34 | -14.3 | 24.56 | -18.72 | 5.5 |
| 5y average | 142.37 | -28.65 | 1.12 | -8.27 | 3.8 |
| Weighted average score | 4.5 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Cash reserves $88.9M barely cover the upcoming debt maturities $0.0
Total current assets $89.9M exceed Total current liabilities $6.6M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is near the industry average, reflecting balanced leverage
Interest coverage ratio (-7,885.0x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$9.3M limits the company's ability to reinvest or pay down debt